MedTrace Logo

Dupilmuab for Atopic Dermatitis Monitored With Noninvasive Imaging.

NCT05265234 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2022-03-03

No results posted yet for this study

Summary

The study is trying to answer the following question: "Can we use non-invasive imaging to evaluate the response of atopic dermatitis (eczema) to Dupixent (dupilumab)?"

Conditions

Interventions

DRUG

Dupilumab

IL-4 antagonist to improve moderate-severe atopic dermatitis

DEVICE

Optical Coherence Tomography

OCT is a noninvasive imaging device that can be used to monitor inflammatory skin disorders.

DEVICE

Reflectance confocal microscopy

RCM is a noninvasive imaging device, with resolution approaching that of histology, which can monitor structural changes in the epidermis and superficial dermis, monitor inflammatory cells, and can overcome the limitations of a traditional biopsy.

Sponsors & Collaborators

Principal Investigators

  • Orit Markowitz, MD · Medical Director

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-03-01
Completion
2024-03-01
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05265234 on ClinicalTrials.gov